Esophageal Cancer Market Report 2026

The esophageal cancer market size has grown strongly in recent years. It will grow from $1.51 billion in 2025 to $1.65 billion in 2026 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to tobacco and alcohol consumption, late-stage diagnosis prevalence, chemotherapy dependence, hospital oncology expansion, aging population.

The esophageal cancer market size is expected to see strong growth in the next few years. It will grow to $2.37 billion in 2030 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to precision oncology adoption, immunotherapy development, early screening initiatives, improved imaging technologies, personalized cancer care. Major trends in the forecast period include rising adoption of targeted cancer therapies, increased use of combination treatment approaches, growth in advanced stage cancer management, expansion of minimally invasive surgical procedures, emphasis on early detection and diagnosis.

An increase in esophageal cancer is expected to drive the growth of the esophageal cancer market. Esophageal cancer is a malignancy affecting the esophagus, the tube connecting the throat to the stomach. As the incidence of esophageal cancer rises, there will be greater demand for diagnostic procedures, including endoscopy, imaging tests, and biopsies, to detect and confirm the disease. For instance, in 2023, the American Cancer Society, a US-based professional organization, reported 16,120 new deaths from esophageal cancer, with projections indicating an increase to 16,130 in 2024. Therefore, the rising incidence of esophageal cancer is expected to propel the growth of the esophageal cancer market.

Major companies in the esophageal cancer market are focusing on product launches, such as precision medicine, to provide personalized approaches for effectively managing cancer risk. Precision medicine tailors medical interventions, including drugs and therapies, to individual patients based on their unique genetic, environmental, and lifestyle factors. For instance, in March 2023, Previse, a US-based biotechnology company specializing in diagnostics, medical devices, and early detection, launched Esopredict, a precision medicine solution that enables gastroenterologists to manage the risk of future esophageal cancer more effectively. This solution utilizes the EsoScore derived from Barrett’s esophagus cells to provide accurate five-year risk predictions, supporting timely and individualized patient management. The product addresses a critical unmet medical need by helping healthcare providers identify patients at risk of developing high-grade dysplasia or esophageal cancer, significantly impacting the esophageal cancer market.

In January 2023, ProPhase Labs, Inc., a US-based biotech, genomics, and diagnostics company, acquired the rights to the BE-Smart Esophageal Pre-Cancer Diagnostic Screening Test from Stella Diagnostics, Inc. Through this acquisition, ProPhase Labs aims to enable healthcare providers to initiate early, potentially life-saving treatments, such as ablation procedures to remove precancerous cells. Stella Diagnostics, Inc. is a US-based molecular diagnostics company dedicated to improving patient management strategies.

Major companies operating in the esophageal cancer market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Seagen Inc., Exelixis Inc., BeiGene Ltd., Clovis Oncology Inc., AbbVie Inc., Bayer AG, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Aslan Pharmaceuticals Ltd., Johnson & Johnson Services Inc., CStone Pharmaceuticals, Shanghai Henlius Biotech, Jiangsu Hengrui Medicine Co Ltd., Kyowa Kirin Co Ltd., Incyte Corporation.

North America was the largest region in the esophageal cancer market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the esophageal cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the esophageal cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the esophageal cancer market by increasing costs of imported oncology drugs, surgical instruments, and diagnostic imaging systems. Hospitals and specialty cancer centers in developed regions are most affected due to reliance on imported therapies. These tariffs raise treatment costs by increasing expenses for chemotherapy, targeted agents, surgical procedures, and advanced imaging, placing pressure on oncology care budgets. However, they encourage domestic production of oncology drugs, supporting regional pharmaceutical manufacturing and supply chain resilience.

The esophageal cancer market research report is one of a series of new reports that provides esophageal cancer market statistics, including esophageal cancer industry global market size, regional shares, competitors with a esophageal cancer market share, detailed esophageal cancer market segments, market trends and opportunities, and any further data you may need to thrive in the esophageal cancer industry. This esophageal cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Esophageal cancer is a type of cancer that develops in the cells lining the esophagus, the muscular tube that transports food and drinks from the throat to the stomach. It occurs when abnormal cells in the esophagus grow uncontrollably, leading to cancer.

The main types of esophageal cancer include esophageal squamous-cell carcinoma, esophageal adenocarcinoma, and others. Esophageal squamous-cell carcinoma arises from the squamous cells that line the esophagus. Treatment options include chemotherapy, targeted therapy, and others, which can be administered orally, parenterally, and via other routes. These treatment products are distributed through hospital pharmacies, online pharmacies, and retail pharmacies, and are used by hospitals, homecare services, specialty centers, and other healthcare facilities.

The esophageal cancer market consists of revenues earned by entities by providing esophageal cancer treatment services such as esophagectomy, palliative care, and brachytherapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The esophageal cancer market consists of sales of fluorouracil, capecitabine, cisplatin, epirubicin, and docetaxel. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.